In an interview on CNBC’s Mad Money, David Ricks said Mounjaro has the potential to help tens of millions of people, and its benefits are just starting to be understood. “I get stories every day from patients about how Mounjaro has positively changed their lives.” By December, monthly output will double from last year’s levels, he noted. There are almost a billion people who could benefit from obesity medications, he added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Lilly Completes Acquisition of DICE Therapeutics
- Eli Lilly price target raised to $580 from $490 at RBC Capital
- Novo Nordisk, Eli Lilly news positive for Terns Pharmaceuticals, says Mizuho
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Eli Lilly price target raised to $630 from $550 at Cantor Fitzgerald